Tonix Pharmaceuticals Holding Corp. (TNXP) said Monday that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for TNX-102 SL for the treatment of major depressive disorder (MDD) in adults.
The IND clearance allows the company to advance to the potentially pivotal Phase 2 HORIZON study, which will evaluate TNX-102 SL as a first-line monotherapy in adults with MDD.
Tonix Pharmaceuticals shares were down more than 2% in pre-market trading after closing at$16.10, up 2.94% on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.